Bio-Rad Laboratories Inc. Class A Common Stock (BIO)
Stock · NYSE · Industrials
$353.6as of 10/16/2026
Price chart
Active signals
BIO Signal Track Record
How signals performed across all stocks →What BIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -0.2% | 50% | September 15, 2026 |
| Bollinger Band Breakout | 27 | -2.8% | 33% | July 23, 2026 |
| Bollinger Band BreakdownActive now | 22 | +3.0% | 64% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 19 | +2.0% | 58% | July 15, 2026 |
| Any 20-session window (baseline) | +0.6% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BIO
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, a…
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Employees
- 7,450
- Website
- www.bio-rad.com/
Fundamentals
- 1-day range
- $354.85$365.16
- Market cap
- $9.16B
- P/E (trailing)
- 43.88
- P/E (forward)
- 36.42
- EPS (trailing)
- $8.25
- Dividend yield
- —
- Beta
- 1.07
- Avg. volume
- 274.2K
How Bio-Rad Laboratories Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Bio-Rad Laboratories Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- BIOBio-Rad Laboratories Inc. Class A Common Stock$353.7▼ 3.05%Market cap $9.16BP/E 43.88$236.73$396.23
- AVTRAvantor Inc. Common Stock$16.42▲ 2.05%Market cap $8.91BP/E —$7.27$16.38
- BRKRBruker Corporation Common Stock$54.8▼ 3.08%Market cap $7.95BP/E —$32.37$66.98
- TXG10x Genomics Inc. Class A Common Stock$69.86▼ 3.49%Market cap $5.79BP/E —$11.62$102.81
- RVTYRevvity Inc. Common Stock$152.64▼ 1.34%Market cap $12.74BP/E 72.12$81.22$166.25
- EYPTEyePoint Inc. Common Stock$2.99▼ 4.78%Market cap $1.08BP/E —$2.93$19.11
- CTKBCytek Biosciences Inc. Common Stock$5.25▼ 2.96%Market cap $537.23MP/E —$3.31$6.21
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BIO Bio-Rad Laboratories Inc. Class A Common Stock | $9.16B | 43.88 | $353.7 | ▼ 3.05% | $236.73$396.23 |
| AVTR Avantor Inc. Common Stock | $8.91B | — | $16.42 | ▲ 2.05% | $7.27$16.38 |
| BRKR Bruker Corporation Common Stock | $7.95B | — | $54.8 | ▼ 3.08% | $32.37$66.98 |
| TXG 10x Genomics Inc. Class A Common Stock | $5.79B | — | $69.86 | ▼ 3.49% | $11.62$102.81 |
| RVTY Revvity Inc. Common Stock | $12.74B | 72.12 | $152.64 | ▼ 1.34% | $81.22$166.25 |
| EYPT EyePoint Inc. Common Stock | $1.08B | — | $2.99 | ▼ 4.78% | $2.93$19.11 |
| CTKB Cytek Biosciences Inc. Common Stock | $537.23M | — | $5.25 | ▼ 2.96% | $3.31$6.21 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- ENGELHARDT EVA ANETTE · May 11, 2026 · Sale550 @ $246.54
- ENLOE COURTNEY C · April 24, 2026 · Option Exercise186
- ENLOE COURTNEY C · April 24, 2026 · Tax Withholding77 @ $287.84
- Lakkaraju Roop Kalyan · April 24, 2026 · Option Exercise1.1K
- Lakkaraju Roop Kalyan · April 24, 2026 · Tax Withholding420 @ $287.84
- Melinda Litherland Pei · April 21, 2026 · Option Exercise407
- Melinda Litherland Pei · April 21, 2026 · Grant369
- PINKSTON ARNOLD A · April 21, 2026 · Option Exercise407
- PINKSTON ARNOLD A · April 21, 2026 · Grant369
- Hinckley Greg K · April 21, 2026 · Option Exercise407
- Hinckley Greg K · April 21, 2026 · Grant369
- EDWARDS JEFFREY L · April 21, 2026 · Option Exercise407
- EDWARDS JEFFREY L · April 21, 2026 · Grant369
Institutional Ownership
March 31, 2026
- Total shares held
- 18.92M
- Total value held
- $5.03B
- Institutional holders
- 384
- Unknown2.60M
- Unknown1.68M
- Unknown1.09M
- Unknown831.2K
- Unknown786.0K
- Unknown588.7K
- Unknown559.6K
- Unknown450.0K
- Unknown445.0K
- Unknown426.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth
The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth. The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.